Medical Cannabis & Organ Transplant Policies
Studies show that medical cannabis patients face reduced access to lifesaving, organ transplant opportunities, often with fatal consequences. Institutional bias within individual transplant programs continues to reinforce outdated assumptions, even though research across kidney, liver, heart, and lung transplantation has yet to identify clinical evidence that medical cannabis exposure alone jeopardizes transplant success. Instead, the available evidence indicates that the most credible cannabis-related risks can be addressed through patient education, product safety standards, disclosure, and careful monitoring. Even in states that prohibit the denial of transplant-related services solely on the basis of medical cannabis patient status, the absence of a national evidence-based standard has allowed inconsistent policies to persist. As a result, organ transplant access remains shaped by lingering stigma rather than clinical evidence.
DOWNLOAD REPORT NOW!
Patients and families experiencing transplant discrimination related to medical cannabis are encouraged to contact Americans for Safe Access by filling out the organ transplant discrimination intake form.
For more information on organ transplants and medical cannabis patients, visit:
Share this page
